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Abstract
Refined vaccines and adjuvants are urgently needed to advance immunization against global infectious challenges such as
HIV, hepatitis C, tuberculosis and malaria. Large-scale screening efforts are ongoing to identify adjuvants with improved
efficacy profiles. Reactogenicity often represents a major hurdle to the clinical use of new substances. Yet, irrespective of its
importance, this parameter has remained difficult to screen for, owing to a lack of sensitive small animal models with a
capacity for high throughput testing. Here we report that continuous telemetric measurements of heart rate, heart rate
variability, body core temperature and locomotor activity in laboratory mice readily unmasked systemic side-effects of
vaccination, which went undetected by conventional observational assessment and clinical scoring. Even minor aberrations
in homeostasis were readily detected, ranging from sympathetic activation over transient pyrogenic effects to reduced
physical activity and apathy. Results in real-time combined with the potential of scalability and partial automation in the
industrial context suggest multiparameter telemetry in laboratory mice as a first-line screen for vaccine reactogenicity. This
may accelerate vaccine discovery in general and may further the success of vaccines in combating infectious disease and
cancer.
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Introduction
Vaccination represents one of the most successful strategies to
control or even eradicate infectious diseases. New approaches to
vaccination are, however, needed to better approach global
challenges such as malaria, tuberculosis, human immunodeficien-
cy virus (HIV) and cancer. Unlike live and vectorized vaccines,
inactivated ones based on whole pathogens or antigenic subunits
thereof generally require the addition of adjuvants for inducing
protective immune response. Aluminium hydroxide and alumin-
ium phosphate adjuvants (alum) have been used for decades in
many such vaccines, despite occasional toxic side-effects [1–4] and
– depending on the context and the immune effector pathways
analyzed – only limited efficacy. Apart from protein-based
vaccines also DNA-based strategies [5,6] require refined adjuvant
systems for optimal efficacy [7–12]. In recent years, much effort
has therefore been devoted to the search for new adjuvants with
superior efficacy and safety [8,13,14], and some of them have
successfully made it to the clinic. Yet, the need for new adjuvants
and vaccine formulations in general remains a priority in
combating diseases where existing strategies have failed to provide
protection [10,15]. In the eyes of many scientists, a systematic
global large-scale approach provides the highest likelihood of
success in this direction [16]. Such an endeavour will, however,
require the development of refined and standardized screening
procedures, both for vaccine efficacy as well as for safety and
reactogenicity.
Current standards in safety testing include clinical scoring for
symptoms of disease, investigation of body fluids (e.g. blood, urine,
faeces) and post mortem pathological examination of several
organs. Thus, teratogenicity, carcinogenicity and organ-specific
long-term toxicity of test compounds are best detected. Irrespec-
tive of the considerable number of experimental animals required
and the financial resources dedicated to the task [17,18], the
information obtained remains incomplete. Less severe reactoge-
nicity can go undetected but may still render many compounds
inappropriate for clinical use. Thus, the need for novel approaches
in preclinical safety screening of adjuvants has become increas-
ingly recognized in recent years [15], and includes notably a
requirement for objective measures of short-term reactogenicity,
which is not commonly born out in long-term health impairment
i.e. teratogenicity, carcinogenicity or persisting histopathological
alterations.
Here we have exploited multiparameter telemetry as a novel
preclinical method for the assessment of vaccine reactogenicity.
Our approach allows the evaluation of test compounds using a
limited number of laboratory mice. We show that the continuous
and combined telemetric measurements of heart rate, heart rate
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suited to detect transient reactogenicity of adjuvants ranging
from sympathetic activation over pyrogenicity to apathy. These
parameters therefore not only detect substantial health impair-
ment but also record signs of minor distress, both in an
investigator-independent and accurate way. Standardized results
in real-time allow for rapid decision-making in the context of
screening projects. This technique will therefore facilitate the rapid
and accurate selection of promising candidate adjuvants and
vaccine formulations, and the early exclusion of reactogenic
compounds. Multiparameter telemetry can thus help saving
financial resources and will speed up the selection and develop-
ment of vaccination approaches with promising safety and
tolerability profiles.
Results
Experimental design
To assess the suitability of multiparameter telemetry for testing
vaccine reactogenicity, we chose two experimental protocols of
bovine herpesvirus 1 (BHV-1) vaccination (Fig. 1). In protocol #1,
inactivated BHV-1 in complete Freund’s adjuvant (CFA) was
injected intraperitoneally (i.p.) for primary immunization (BHV-1/
CFA) followed by a booster immunization in incomplete Freund’s
adjuvant (IFA) 28 days later (BHV-1/IFA). Protocol #2 consisted
of one single intraperitoneal administration of live BHV-1 without
addition of adjuvants. Protocol #1 reflected therefore a prototype
vaccination regimen, which does not meet modern criteria for
safety and tolerability, whereas apathogenic viral particle formu-
lations as exemplified in protocol #2 are self-adjuvanted. Hence,
they do not normally require the addition of chemical adjuvants
and their tolerability compares favourably to the former one. The
BHV-1-specific antibody response and IgG subclass repartition
was monitored 2 weeks after primary immunization (day post
immunization (dpi) 14) and booster vaccination (dpi 42),
respectively, and demonstrated satisfactory immunogenicity of
both protocols.
Antigen and vaccine formulations as well as methods and results
for assessment of serum antibody response to BHV-1 can be found
as supporting information (Text S1; Fig. S1).
To estimate potential adverse effects related solely to the
injection procedures, animals were given sham injections two
weeks before immunization (dpi –14). For this, the vehicle solution,
containing neither BHV-1 nor adjuvant, was administered
intraperitoneally. Telemetric transmitters were implanted prior
to the sham injections to record in real-time and on the long-term
not only heart rate but also interbeat interval, heart rate
variability, body core temperature and locomotor activity.
Recordings started one day before each injection to obtain
baseline values and continued for three days after injection. On
each of these days, a clinical assessment was performed, too.
Additional groups of mice were subject to protocol #1 and #2,
but were euthanized for macroscopic inspection and histological
analysis of the abdominal organs three days after primary (dpi 3)
and booster immunization (dpi 31), respectively.
Clinical scoring fails to detect vaccine reactogenicity
For clinical scoring, sixteen mice (eight animals/protocol) were
examined for appearance, posture, spontaneous and provoked
movement and behaviour. In addition, body weight as well as food
and water consumption were measured. These widely used
parameters were chosen as read-outs of pain and discomfort or
global impairment of health in small rodents. By these criteria,
even a very thorough examination by an experienced veterinarian,
Figure 1. Experimental design. Eight mice per immunization protocol were equipped with telemetric transmitters for real-time, long-term
recording of heart rate, interbeat interval, heart rate variability (standard deviation of interbeat interval), body core temperature and locomotor
activity. Simultaneous clinical scoring included body weight measurements, as well as food and water consumption. Measurements were conducted
over a period of four days (grey), the first of which served as individual baseline. Antibody responses were determined in serum samples collected
two weeks after primary and booster immunization, respectively (triangles). Twenty-two mice without transmitter were treated analogously and were
sacrificed for gross pathology of abdominal organs and blinded histological analysis of intestine, omentum, abdominal wall, and liver at three days
after primary and booster immunization (arrows), respectively.
doi:10.1371/journal.pone.0029726.g001
Telemetry Detects Vaccine Reactogenicity
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29726specialized on small rodents, failed to detect abnormalities. None
of the animals exhibited diarrhoea, ruffled fur, sunken flanks,
enlarged abdomen, hunched posture, gait abnormalities, slowed
movement, apathy or any other visible sign of discomfort.
A trend to decreased food and water consumption was noted
in animals undergoing vaccination protocol #1 (Fig. 2). Food
consumption was significantly reduced by 19+/25% (mean+/
2SEM; p=0.008) on the first day after primary immunization.
Water consumption decreased by 22+/27% (mean+/2SEM;
p=0.009) on day 2 after primary immunization. Body weight
showed a slight tendency to decrease during primary immuniza-
tion in protocol #1. Conversely, not even a tendency of adverse
effects was detected by these clinical parameters when assessing
animals in protocol #2. It therefore seems likely that the above
parameters could have detected reactogenicity of vaccination
protocol #1, but only if analyzed in substantially larger groups of
animals. This classical approach was therefore not well suited for
high-throughput screening of vaccine reactogenicity.
Organ pathology
Twenty-two mice, which had not received telemetry transmit-
ters, were sacrificed on day three after primary (dpi 3) and booster
immunization (dpi 31), respectively, to assess adverse effects at the
injection site, i.e. in the peritoneal cavity. Gross macroscopic
inspection of the abdominal organs failed to reveal any alterations.
Conversely, microscopic analysis detected considerable patholog-
ical changes in liver, intestine, omentum and abdominal wall of the
mice in vaccination protocol #1. Multifocal or even coalescing
inflammatory infiltrates were mostly found in the fatty tissue of the
omentum (Fig. 3, B–D) but also on the serosal surface of the liver
and abdominal wall (Fig. 3, E, F). On day 3 after primary
immunization with BHV-1/CFA, infiltrates consisted mainly of
neutrophilic granulocytes (Fig. 3, E) consistent with acute, largely
non-specific inflammation. Upon booster immunization with
BHV-1/IFA, the infiltrates consisted mostly of lymphocytes and
histiocytes, occasionally interspersed with multi-nucleated giant
cells (Fig. 3, F) compatible with chronic and/or specific
inflammation. In contrast, protocol #2 did not provoke any of
these abnormalities (Fig. 3, A, G).
The occurrence and severity of histological changes were
scored, revealing overall very significant differences between the
two immunization protocols (Table 1, p=0.0005). On day three
after primary immunization with BHV-1/CFA (protocol #1),
tissue alterations were mild to moderate. More severe changes
Figure 2. Changes in body weight, and food and water intake. Data were plotted over four days at sham injection, primary and booster
immunization. The first data point of each series represents baseline values taken the day before an intraperitoneal injection (grey-filled symbols).
Symbols indicate daily mean of eight mice per protocol, bars indicate SEM. Asterisks indicate statistical significance with p#0.01.
doi:10.1371/journal.pone.0029726.g002
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animals undergoing immunization with live BHV-1 (protocol #2)
exhibited histopathological alterations of grade I, which was
significantly lower than in protocol #1 (p=0.003).
In summary, histopathology detected vaccination-related in-
flammatory alterations, which were not readily born out when
clinically assessing the animals. Adjuvants are, however, aimed at
mimicking pathogen-associated molecular patterns (PAMPs), with
the goal of eliciting inflammation and consequent immunostim-
ulation at the site of injection. It can therefore be difficult to
interpret the clinical significance of local histopathological
changes, particularly with regard to systemic side-effects and
tolerability.
Telemetric measurements
We thus attempted to overcome the existing shortcomings in
screening methods for safety and tolerability of vaccines. Mice
were equipped with commercially available telemetry transmitters,
allowing continuous long-term measurements of their heart rate,
heart rate variability, body core temperature and locomotor
activity while the animals are freely roaming. After implantation of
the transmitter and a resting period, the mice underwent
vaccination. Telemetric recording was performed over a period
of 96 hours, and started 24 hours before administration of the
vaccine to assess individual baseline values.
In animals undergoing vaccination protocol #1, heart rate
increased, whereas the heart interbeat interval and heart rate
Figure 3. Histological grading of inflammation. (A–D) Representative examples of inflammation grades I–III in hematoxylin/eosin-stained
sections of the omentum: Grade I: normal (A); Grade II: mild to moderate inflammation, with focal infiltrates (B, C); Grade: III severe inflammation,
diffuse infiltrates (D). (E–G) Representative hematoxylin/eosin-stained sections of the abdominal wall from protocol #1 and protocol #2a td p i3( 3
days after primary immunization) (E, G) and from protocol #1 at dpi 31 (3 days after booster immunization) (F). Mild inflammatory infiltrates (Grade II)
consisting mainly of neutrophils (inset) are visible in the serosa after primary immunization with inactivated virus in CFA (protocol #1, dpi 3) (E). After
booster immunization with inactivated virus in IFA (protocol #1, dpi 31) the serosa of the abdominal wall is infiltrated with severe, diffuse
inflammatory aggregates (Grade III) consisting mainly of lymphocytes and histiocytes (F). No abnormalities (Grade I) are detectable at 3 days after
immunization with live virus (protocol #2, dpi 3) (G). Bars represent 50 mm.
doi:10.1371/journal.pone.0029726.g003
Table 1. Summary of local intra-abdominal side-effects.
histological grading I (none) II (mild to moderate) III (severe)
inactivated virus in adjuvant (protocol 1) 3 days after primary immunization (dpi 3) 9/9
inactivated virus in adjuvant (protocol 1) 3 days after booster immunization (dpi 31) 1/6 5/6
live virus (protocol 2) 3 days after primary immunization (dpi 3) 7/7
doi:10.1371/journal.pone.0029726.t001
Telemetry Detects Vaccine Reactogenicity
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29726variability (standard deviation of interbeat interval) decreased
(Fig. 4). In mice, these alterations are typically seen as a result of
pain or distress [19]. These changes on the first day after primary
and secondary immunization were statistically highly significant
with p between 0.01 and 0.0005. Perturbation of the standard
deviation of interbeat interval persisted even throughout the
second day after primary immunization (p=0.001) and is
commonly used as an indicator of sympathetic activation [20],
and thus of a stress response [21]. Unlike vaccination protocol #1,
protocol #2 consisting of live BHV-1 did not elicit significant
alterations in any of the above parameters. Further, sham injection
failed to affect heart rate, interbeat interval or standard deviation
of the latter, confirming that neither the injection procedures nor
the vaccine carrier solutions but the adjuvant accounted for the
pathophysiological changes observed in protocol #1.
Hyperthermia, i.e. elevated body core temperature, is indicative
of pyrogenicity, e.g. the effects of lipopolysaccharide and other
pathogen-associated molecular patterns [22]. In vaccination
protocol #1, hyperthermia was evident after the primary
immunization in CFA, but not after the booster immunization
in IFA (p=0.003, Fig. 4). Whether hyperthermia was due to
adjuvant or antigen or the combination thereof remains uncertain,
but given the known reactogenicity profile of CFA, adjuvant likely
has a contribution [23].
In accordance with the above parameters of the animal’s
wellbeing, telemetry detected also decreased locomotor activity in
animals undergoing vaccination protocol #1. This alteration
persisted for two days after primary immunization (p#0.006) and
for one day after booster vaccination (p=0.007), whereas
vaccination protocol #2 or sham injections failed to exert
analogous effects (Fig. 4).
Interestingly, the telemetric parameters did not provide a direct
quantitative correlate to the histopathological grading of inflam-
mation i.e. the higher degree of histopathological inflammation
upon secondary immunization (Table 1) did not augment
disturbance of telemetric parameters (Fig. 4). This observation
can serve as an example of the difficulty in correlating clinical
manifestations with post-mortem observations on tissues, and
provides further impetus for screening procedures such as
telemetry, which involve the living animal.
Discussion
The present study demonstrates the utility and sensitivity of
telemetry for detection of adverse inflammatory effects of vaccine
adjuvants. The comparison to more conventional approaches of
clinical examination and histopathology has highlighted the
obvious advantages of the method. By recording sympathetic
activation, pyrogenicity and apathy in the free-ranging, untethered
mouse, telemetry readily detected vaccine reactogenicity. Notably,
these systemic side-effects of vaccination were not detected by
clinical examination but were validated in histopathological
analyses. The simultaneous detection of vaccine reactogenicity
by multiple read-outs such as heart rate, interbeat interval, body
core temperature and locomotor activity represents a clear
advantage over more simple approaches with only one or two
parameters recorded [24]. Not only are multiple parameters well
suited to increase the sensitivity of the assessment, but they also
can raise confidence in the result of an adverse reaction if multiple
parameters evidence it. Albeit seemingly superior to classical
methods of reactogenicity screening, future refinement of the
methodology and parameters may further increase the sensitivity
and specificity of the telemetry described herein. Accordingly it
remains possible that e.g. live BHV-1 administration caused minor
side-effects, which went undetected by the present methods.
Whether or not such minor discomfort would translate into an
acceptable clinical reactogenicity profile remains to be assessed in
future work.
Laboratory mice are widely considered an optimal mammalian
model organism for research and development of pharmaceutical
products. The short reproductive cycle of mice, a high level of
standardization owing to inbreeding and genetic homogeneity as
well as ethical and economical considerations speak in its favour.
In the context of compound reactogenicity and toxicity testing,
however, these advantages were formerly often outweighed by the
fairly limited information retrievable from clinical examination
and observational assessment. Only severe symptoms of disease
are readily reflected in appearance, posture and spontaneous
behaviour. As prey animals, the mouse has supposedly evolved to
hide distress in order to avoid attracting predators [25–27]. This
behavior is also prompted by an investigator approaching the
animal’s cage. Moreover, merely the touching, handling or
restraining – all of which are needed for detailed investigation –
induce immediate alterations in heart rate, body core temperature
[28], and blood pressure. These confounding factors have greatly
complicated the reliable measurement of physiological parameters
in mice, suggesting that data acquisition independently of an
investigator’s presence could offer an important step forward.
Hence, telemetry as used in this study may provide the missing
element to make the mouse model amenable to reactogenicity
testing. Besides this key advantage, continuous reporting of data
avoids any potential bias related to snapshot images in time.
Additionally, continuous data recording allows various retrospec-
tive detailed analyses (e.g., circadian rhythmicity, differentiation
between the night and daylight phase as shown in Fig. S2, and Fig.
S3) and thus can reveal even subtle or transient alterations.
Telemetry also is standardized, avoiding potential investigator-
related variations in assessment. The possibility for automated
real-time evaluation may be particularly relevant when it comes to
screening of large compounds libraries, facilitating rapid decision-
making by automated processes. Histopathology has confirmed
the telemetric observations in this study and may in the future also
provide an independent second line methodology to confirm
screening results where needed. Similarly, larger animal models
will remain a necessity for moving suitable candidate adjuvants
towards clinical trials, not only for the assessment of their safety
profile, but importantly also for immunogenicity and efficacy
testing.
Taken together, this study demonstrates the utility of multipa-
rameter telemetry in mice as a first-line screening approach for
candidate vaccine adjuvant compounds. Using only limited
numbers of mice, this method allows for their automated
evaluation, differentiation and selection without sizeable risk for
investigator-related bias. The early focussing on well tolerated test
compounds and the possibility for up-scaling and partial
automation in the industrial context bear considerable potential
for rapidly advancing adjuvant discovery. This will not only help
reducing animal testing, but, equally importantly, such methods
can save precious time and will help channelling the limited
financial resources available to more efficiently combat pressing
global health problems.
Methods
Ethics statement
Ethical justification of the study as well as animal care and use
were approved by the Cantonal Veterinary Office (Zurich,
Switzerland) under license number 39/04. Housing and experi-
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29726Figure 4. Telemetric assessment of vaccine reactogenicity. Heart rate [beats per minute, bpm], interbeat interval [milliseconds, ms], standard
deviation of interbeat interval [milliseconds, ms], body core temperature [uC] and locomotor activity [counts] were recorded by telemetry and are
displayed over three four-day periods at sham injection, primary and booster immunization, respectively (compare Fig. 1). The first data point of each
series represents baseline values taken the day before an intraperitoneal injection (grey-filled symbols). Symbols indicate 24-hour means of eight
mice per protocol, bars indicate SEM. Asterisks indicate statistical significance with p#0.01. Note increased heart rate values with decreased interbeat
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protection law and in conformity with the European Convention
for the protection of vertebrate animals used for experimental and
other scientific purposes (Council of Europe nr.123 Strasbourg
1985). Housing and experimental procedures were also in
accordance with the Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources, National
Research Council, National Academy of Sciences, 1996).
Mice: health status, housing and experimental conditions
Thirty-eight female mice of the strain 129Sv/Ev-IFNabRtmAgt
(A129) [29] were randomly allocated to protocols and transmitter
implantation or pathological analyses. These interferon receptor
type I deficient mice were chosen owing to their widespread usage
as highly virus-susceptible hosts, albeit fairly resistant to the BHV-
1 infection used in this work [30]. Mice were free of all viral,
bacterial, and parasitic pathogens listed in the recommendations of
the Federation of European Laboratory Animal Science Associ-
ations [31]. Health status was confirmed by a health surveillance
program throughout the experiment.
Mice were kept individually in filter top plastic cages
(425 mm6266 mm6150 mm, floor area 820 cm
2) with auto-
claved dust-free sawdust bedding (80–90 g per cage) and
autoclaved hay (8–10 g per cage) as nesting material. Each cage
was equipped with a plastic shelter (Mouse house
TM, Indulab,
Gams, Switzerland). Animals were fed a pelleted standard mouse
diet (Kliba No. 3436, Provimi Kliba, Kaiseraugst, Switzerland) ad
libitum, and had free access to sterilized drinking water. The light/
dark cycle in the room consisted of 12/12 h (07:00–19:00) of
artificial light. The climate was 2161uC, with a relative humidity
of 5065%, and with 15 complete changes of filtered air per hour
(HEPA H 14 filter).
All mice were bred and housed throughout the experiments in
the same mouse room under biosafety conditions. The animal
room was isolated from electronic noise and no disturbances (e.g.
visitors or unrelated experimental procedures) were allowed. To
avoid interfering influences, all necessary husbandry procedures
were completed in the room three days before starting each
measurement. All experimental procedures (i.e. injections, clinical
scoring including weighing, blood sampling, necropsy) were
carried out at the same time of day, 16.00 to 18:00 h, i.e. 1–
3 hours before the onset of night phase in the animal room.
Implantation of telemetric transmitters
Telemetric transmitters were implanted at 10 weeks of age. The
TA10ETA-F20 transmitters (Data Sciences International, St. Paul,
MN, USA), which are able to process heart rate, electrocardio-
gram, body core temperature, and locomotor activity in freely
moving mice, were implanted as previously described [32]. Briefly,
under anaesthesia with ketamine (Ketasol-100
TM, Graub, Bern,
Switzerland), 45 mg/kg body weight, subcutaneously, and iso-
flurane (Isoflo
TM, Abbott, Baar, Switzerland) 3–5% in oxygen via
nose mask, the telemetric transmitter body was implanted under
aseptic conditions into the abdominal cavity. One telemetry lead
was sutured as a wired loop to the xiphoid process. The other lead
was tunneled subcutaneously from the thorax to the neck, where
the wired loop electrode was fixed between the muscles located to
the right of the trachea. Post-operative pain was treated with
buprenorphine (Temgesic
TM, Reckitt and Colman Products Ltd.,
Hull, England), at a dose of 0.1 mg/kg bodyweight, injected
subcutaneously twice per day for 4 days. After transmitter
implantation, the mice had a period of 8 weeks convalescence
until the start of the measurements and injection of the test
compounds.
Clinical scoring, acquisition of telemetric data and their
evaluation
Clinical scorings and telemetric measurements were recorded in
4-day-periods for sham, primary and booster immunization
respectively. The first day of each monitoring period was a
control measurement, i.e. the day before the injection of a test
compound represented baseline values. Recordings continued for
3 days following an intraperitoneal injection, to document the
impact of the test substances.
Telemetric measurements were processed using the Dataquest
LabPRO program, version 3.11 (Data Sciences International, St.
Paul, MN, USA). The telemetric transmitter was switched on by
touching the animal with a magnet; signals were detected by a
receiver plate placed underneath the animal’s cage.
Heart rate and electrocardiogram curves were recorded for
30 seconds every 5 minutes (sampling frequency 1000 Hz). Heart
rate, interbeat interval and heart rate variability (standard
deviation of interbeat interval) were established with commercially
available software (Dataquest LabPRO program, version 3.11,
Data Sciences International, St. Paul, MN, USA) by calculating
the number of R-peaks and by determining the distance between
R-peaks in the electrocardiogram curve. Electrocardiogram curves
were subjected to a time domain analysis of heart rate variability as
defined [20,33,34]: the interbeat interval and the standard
deviation of interbeat interval were calculated from each segment
measured. The standard deviation of interbeat interval was
calculated as the standard deviation of interbeat intervals from
normalized R-peaks in each 30-second measuring segment, and
represents the variability in heart rate changes. Body core
temperature was sampled for 10 seconds every 5 minutes.
Locomotor activity was measured by the horizontal displacement
of the animal in relation to two antennas in the receiver plate and
was expressed in ‘activity counts’. Locomotor activity was
recorded continuously and stored at 5 minute intervals. Telemet-
ric data were calculated as mean of 24 hours.
Clinical scoring was carried out once daily. First, the animal’s
home cage was examined for any hints on health impairment (e.g.,
abnormal feces) or distress (e.g., unstructured cage area, poor nest
building performance). If the animal was not hidden in that it was
sleeping or resting in its nest, it was observed shortly in its home
cage for aberrations of posture and spontaneous movement
behaviour. Then, before weighing the animal, it was set on the
cage lid to be investigated for clinical signs of illness or disease,
such as diarrhoea, ruffled fur, abnormal posture, discharge of eyes,
enlargement of abdomen, sunken flanks, or any other visible
abnormalities. The subsequent weighing procedure normally
provokes the mouse to express reactions such as flight or attention,
which are particularly apparent after the animal is returned to its
cage. Therefore, mice were observed for some seconds after
weighing to register abnormalities in behaviour and movement,
such as lameness, slowed movement or apathy.
Values of body weight, food and water consumption were
established by weighing the animal, the food pellets and water
interval and standard deviation of interbeat interval after primary and booster immunization with inactivated BHV-1 in Freund’s adjuvant. Further,
hyperthermia was noted after primary immunization, and depressed locomotor activity was recorded after primary and booster immunization with
inactivated BHV-1 in Freund’s adjuvant.
doi:10.1371/journal.pone.0029726.g004
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Toledo AG, Greifensee, Switzerland) especially designed to weigh
moving animals. Body weights were corrected to take into account
the weight of the transmitter (3.6 g). Daily values after intraper-
itonal injection of test compounds were compared with baseline
values to identify the individual animals’ changes in food and
water consumption and change in body weight progression.
Pathology
Nine mice of protocol #1 and 7 mice of protocol #2 were
sacrificed by cervical dislocation and necropsied on day three after
primary immunization (dpi 3). Six mice that had received primary
and booster immunizations according to protocol #1 were
necropsied 3 days after the booster immunization (dpi 31).
At necropsy the abdominal organs were macroscopically
examined for any pathological changes. For histological investi-
gation, the liver, samples of intestine, omentum and abdominal
wall were fixed in 4% neutral buffered formalin and processed
routinely. Tissue sections (2 mm) were stained with hematoxylin
and eosin. Histopathological changes were evaluated in a scoring
system ranging from I to III according to severity and distribution
(I=no abnormalities, II=mild to moderate, III=severe; as
exemplified in Fig. 3, A–D). Two pathologists independently
evaluated each tissue samples in a blinded fashion.
Statistical analysis
Results were analyzed statistically using the SPSS 17.0 software
(SPSS Inc., Chicago, USA). Means and standard error of mean
(SEM) were calculated for telemetric values, body weight, food
and water consumption.
All data were tested for normal distribution with Q-Q plot and
adapted Kolmogorov-Smirnov test. Homogeneity of variance was
tested with Levene test. Measures of telemetric values, body
weight, food and water consumption met the necessary assump-
tions for parametric analyses, while pathological results were not
normally distributed and therefore tested with non-parametric
tests. Thus, pathological results were analyzed with the Kruskal-
Wallis H-Test for overall group comparison and Mann-Whitney
U-Test for inter-group comparisons. Dependent t-tests for paired
samples were used to analyze changes on days 1, 2, 3 after
intraperitoneal injection in telemetric values, body weight, food
and water consumption compared to the baseline values at one
day prior to injection.
All tests were performed in two-sided manner. For multiple
comparisons, Bonferroni correction was applied. Thus, signifi-
cance for all statistical tests was established at alpha=0.01
respectively p#0.01.
Supporting Information
Figure S1 Antibody response to vaccination. BHV-1
specific antibody titers of sera taken at dpi 14 (A: response to
primary immunization) or dpi 42 (B: following booster vaccination
in protocol #1, compare Fig. 1.) were determined by IgG subclass-
specific ELISAs. Both live virus and inactivated virus in adjuvant
induced an IgG2a-dominated antibody response indicative of a T
helper 1-like immune response (A). Columns represent the
mean+/2SEM of 6–7 mice per protocol. The dashed line
indicates the limit of detection. Analysis of pre-immune sera
confirmed that all mice were BHV-1-naive before immunization
(data not shown). In each protocol, 1–2 individuals did not
respond to primary immunization and were excluded from the
analysis displayed in this figure.
(TIF)
Figure S2 Time course of heart rate, interbeat interval,
and standard deviation of interbeat interval at the night
and light phase of each day. Heart rate [beats per minute,
bpm], interbeat interval [milliseconds, ms], and standard deviation
of interbeat interval [milliseconds, ms] were recorded by telemetry
and are displayed over three four-day periods at sham injection,
primary and booster immunization, respectively (compare Fig. 1).
The first data point of each series represents baseline values taken
the day before an intraperitoneal injection. Symbols indicate 12-
hour means of eight mice per protocol for the night and light
phase of each day. Bars indicate SEM, asterisks indicate statistical
significance with p#0.01. Note increased heart rate values with
decreased interbeat interval and standard deviation of interbeat
interval after primary and booster immunization with inactivated
BHV-1 in Freund’s adjuvant.
(TIF)
Figure S3 Time course of body core temperature and
locomotor activity at the night and light phase of each
day. Body core temperature [uC] and locomotor activity [counts]
were recorded by telemetry and are displayed over three four-day
periods at sham injection, primary and booster immunization,
respectively (compare Fig. 1). The first data point of each series
represents baseline values taken the day before an intraperitoneal
injection. Symbols indicate 12-hour means of eight mice per
protocol for the night and light phase of each day. Bars indicate
SEM, asterisks indicate statistical significance with p#0.01. Note
hyperthermia after primary immunization, and depressed loco-
motor activity after primary and booster immunization with
inactivated BHV-1 in Freund’s adjuvant.
(TIF)
Text S1
(DOC)
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